The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey
Authors:
- Abdel Magid BakheitABAbdel Magid Bakheit
- Benjamin ZakineBZBenjamin Zakine
- Pascal MaisonobePMPascal Maisonobe
- Claire AymardCAClaire Aymard
- Klemens FhedoroffKFKlemens Fhedoroff
- Harold HefterHHHarold Hefter
- Jorge JacintoJJJorge Jacinto
- Wolfgang H. JostWJWolfgang H. Jost
- Franco MolteniFMFranco Molteni
- Henk StamHSHenk Stam
- Lynne Turner-StokesLTLynne Turner-Stokes
- Jorg WisselJWJorg Wissel
- 1 September 2010
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Rehabilitation Research
- Vol. 33 (3) , 199-204
Abstract
To document the current practice in relation with the treatment of patients with upper limb spasticity with botulinum toxin type A to inform future research in this area. We designed an international, cross-sectional, noninterventional survey of current practice. Nine hundred and seventy-four patients from 122 investigational centres in 31 countries were studied. Most patients were over 40 years old and had a stroke. Improvement of active function was the most frequent treatment goal in the first 3 months after the onset of upper limb spasticity, but was less common than passive function in the chronic stage. Pain relief was a common goal in both the stages. As a rule, clinicians intended to assess the effectiveness of treatment with impairment level scales. Functional outcome measures seem to be rarely used in clinical practice. The use of these measures should be encouraged to assess whether the reduction in muscle tone translates into functional benefit to patients and their caregivers.Keywords
This publication has 13 references indexed in Scilit:
- The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cyclesJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticityJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a StrokeNew England Journal of Medicine, 2002
- Botulinum toxin (Dysport(R)) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging studyJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Botulinum Toxin Type A Neuromuscular Blockade in the Treatment of Lower Extremity Spasticity in Cerebral Palsy: A Randomized, Double-Blind, Placebo-Controlled TrialJournal of Pediatric Orthopaedics, 2000
- A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Botulinum toxin type A in the treatment of upper extremity spasticityNeurology, 1996
- Dose‐response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type ANeurology, 1996
- Botulinum toxin A for spasticity, muscle spasms, and rigidityNeurology, 1995
- Goal attainment scaling: A general method for evaluating comprehensive community mental health programsCommunity Mental Health Journal, 1968